scholarly journals SnoN Is a Cell Type-specific Mediator of Transforming Growth Factor-β Responses

2005 ◽  
Vol 280 (13) ◽  
pp. 13037-13046 ◽  
Author(s):  
Krishna P. Sarker ◽  
Sylvia M. Wilson ◽  
Shirin Bonni
Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3099
Author(s):  
Vivian Weiwen Xue ◽  
Jeff Yat-Fai Chung ◽  
Cristina Alexandra García Córdoba ◽  
Alvin Ho-Kwan Cheung ◽  
Wei Kang ◽  
...  

Transforming growth factor-β (TGF-β) was originally identified as an anti-tumour cytokine. However, there is increasing evidence that it has important roles in the tumour microenvironment (TME) in facilitating cancer progression. TGF-β actively shapes the TME via modulating the host immunity. These actions are highly cell-type specific and complicated, involving both canonical and non-canonical pathways. In this review, we systemically update how TGF-β signalling acts as a checkpoint regulator for cancer immunomodulation. A better appreciation of the underlying pathogenic mechanisms at the molecular level can lead to the discovery of novel and more effective therapeutic strategies for cancer.


1990 ◽  
Vol 4 (7) ◽  
pp. 965-972 ◽  
Author(s):  
Hiromichi Tamada ◽  
Michael T. McMaster ◽  
Kathleen C. Flanders ◽  
Glen K. Andrews ◽  
Sudhansu K. Dey

1998 ◽  
Vol 273 (50) ◽  
pp. 33239-33246 ◽  
Author(s):  
Raymond S. Maul ◽  
Hongxing Zhang ◽  
James D. Reid ◽  
Nancy G. Pedigo ◽  
David M. Kaetzel

2006 ◽  
Vol 36 (3) ◽  
pp. 591-600 ◽  
Author(s):  
Magdalena I Suszko ◽  
Teresa K Woodruff

Members of the transforming growth factor-β (TGFβ) family control diverse cellular responses including differentiation, proliferation, controlled cell death and migration. The response of a cell to an individual ligand is highly restricted yet the signaling pathways for TGFβ, activin and bone morphogenic proteins share a limited number of receptors and activate similar intracellular cytoplasmic co-regulators, Smads. A central question in the study of this family of ligands is how cells titrate and integrate each TGFβ-like signal in order to respond in a cell- and ligand-specific manner. This study uses the pituitary gonadotrope cell line, LβT2, as a model to delineate the relative contribution of TGFβ and activin ligands to follicle-stimulating hormone (FSH) biosynthesis. It was found that pituitary gonadotrope cells do not express the TGFβ type II (TβRII) receptor and are therefore not responsive to the TGFβ ligand. Transfection of the receptor restores TGFβ signaling capabilities and the TGFβ-mediated stimulation of FSHβ gene transcription in LβT2 cells. Consequently, we evaluated the presence of the TβRII in the adult mouse pituitary. TβRII does not co-localize with FSH-producing cells; however it is detected on the cell surface of prolactin- and growth hormone-positive cells. Taken together, these results suggest that the bioavailability of the TGFβ-specific receptor rather than TGFβ dictates pituitary gonadotrope selectivity to activin, which is necessary to maintain normal reproductive function. It is likely that the ligand-restricted mechanisms employed by the gonadotrope are present in other cells, which could explain the distinct control of many cellular processes by members of the TGFβ superfamily.


Sign in / Sign up

Export Citation Format

Share Document